Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer

Cancer Science

Volumn 101, Issue 4, 2010, Pages 934-940

  Zhang, Youwei ^a   Song, Haizhu ^a   Miao, Yufeng ^a   Wang, Rui ^a   Chen, Longbang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GENOMIC DNA; KALLIKREIN; KALLIKREIN 10; MESSENGER RNA; UNCLASSIFIED DRUG; KLK10 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION TERMINATION; TUMOR SUPPRESSOR GENE; CASE CONTROL STUDY; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE SILENCING; HUMANS; KALLIKREINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 77957281534     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01486.x     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 2002; 1: 49-52.
3. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-74.
4. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003; 94: 589-92.
5. Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008; 7: 81.
6. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009; 284: 32989-94.
7. Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 1996; 56: 3371-9.
8. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998; 58: 4782-6.
9. Li B, Goyal J, Dhar S et al. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res 2001; 61: 8014-21.
10. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol 2005; 26: 324-36.
11. Huang W, Zhong J, Wu LY et al. Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett 2007; 251: 78-85.
12. Lu CY, Hsieh SY, Lu YJ et al. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma. Genes Chromosomes Cancer 2009; 48: 1057-68.
13. Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou ES. Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Ann Oncol 2009; 20: 1020-5.
14. Planque C, Aïnciburu M, Heuzé-Vourc'h N, Régina S, de Monte M, Courty Y. Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues. Biol Chem 2006; 387: 783-8.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method. Methods 2001; 25: 402-8.
16. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000; 11: 54-60.
17. Planque C, Li L, Zheng Y et al. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res 2008; 14: 1355-62.
18. Talieri M, Li L, Zheng Y et al. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer 2009; 100: 1659-65.
19. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-90.
20. Petraki CD, Karavana VN, Luo LY, Diamandis EP. Human kallikrein 10 expression in normal tissues by immunohistochemistry. J Histochem Cytochem 2002; 50: 1247-61.
21. Luo LY, Grass L, Diamandis EP. Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. Clin Chim Acta 2003; 337: 115-26.
22. Huang W, Tian XL, Wu YL et al. Suppression of gastric cancer growth by baculovirus vectormediated transfer of normal epithelial cell specific-1 gene. World J Gastroenterol 2008; 14: 5810-5.
23. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al. The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 2004; 18: 362-5.
24. Luo LY, Rajpert-De Meyts ER, Jung K, Diamandis EP. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 2001; 85: 220-4.
25. Feng B, Xu WB, Zheng MH et al. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol 2006; 21: 1596-603.
26. Shvartsman HS, Lu KH, Lee J et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 2003; 90: 44-50.
27. Santin AD, Diamandis EP, Bellone S et al. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. Am J Obstet Gynecol 2006; 194: 1296-302.
28. Rückert F, Hennig M, Petraki CD et al. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br J Cancer 2008; 99: 1484-92.
29. Pettus JR, Johnson JJ, Shi Z et al. Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity. Histol Histopathol 2009; 24: 197-207.
30. Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res 2009; 69: 3779-87.
31. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005; 26: 1481-7.
32. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-65.
33. Cheng C, Omura-Minamisawa M, Kang Y, Hara T, Koike I, Inoue T. Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci 2009; 100: 303-9.
34. Hsu HS, Chen TP, Hung CH et al. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 2007; 110: 2019-26.
35. Wang Y, Yu Z, Wang T et al. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007; 56: 289-94.